Vicapsys Life Sciences, Inc. (VICP)
| Market Cap | 46.94M -18.1% |
| Revenue (ttm) | n/a |
| Net Income | -1.35M |
| EPS | -0.04 |
| Shares Out | 32.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 445 |
| Open | 1.450 |
| Previous Close | 1.460 |
| Day's Range | 1.450 - 1.450 |
| 52-Week Range | 0.150 - 1.750 |
| Beta | 424,349.76 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About Vicapsys Life Sciences
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics Internati... [Read more]
Financial Performance
Financial StatementsNews
ViCapsys Life Sciences Appoints Three New Board Members
Mr. Richard Rosenblum, Dr. Colleen Delaney, and Mr. Charles Farrahar Appointed to the Board of Directors Bring a Combined 75 Years of Financial and Pharmaceutical Expertise SUWANEE, GA / ACCESSWIRE / ...